Costas Lyssiotis, PhD

Assistant Professor of Molecular and Integrative Physiology
Accepting Students

Biography

Costas A. Lyssiotis obtained his bachelor’s degree in Chemistry and Biochemistry from the University of Michigan in 2004, his PhD in Chemical Biology from The Scripps Research Institute in 2010, and then completed postdoctoral training in the laboratory of Lewis C. Cantley at Harvard and Cornell. In 2015, Dr. Lyssiotis joined the faculty at the University of Michigan with appointments in the Departments of Physiology and Medicine. His lab studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Ultimately, his group aims to transition new information about these processes into targeted therapies for cancer and other diseases. He is the recipient of several junior scholar awards including being named a Lefkofsky Scholar, a Kimmel Scholar, an AACR NextGen young investigator, a Dale F. Frey Breakthrough Scientist, and a V Foundation Fellow.

Research Interests

The growth of a tumor, just like the growth of a cell or an organism, requires nutrients and a means to convert nutrients into energy and the basic building blocks that support life. These metabolic processes are frequently deregulated in cancer cells to facilitate growth and enable survival. The Lyssiotis laboratory uses a multi-disciplinary approach encompassing methods in chemistry and biology to define how metabolism is rewired in cancer and then to employ this understanding in the design of targeted tumor metabolism-based therapies.

Research Opportunities for Rotating Students

Publications

 

Halbrook CJ, Pontious C, Lee H-J, Kovalenko I, Zhang Y, Lapienyte L, Dreyer S, Kremer DL, Zhang L, Sajjakulnukit P, Zhang L, Nelson B, Hong H, Kemp S, Chang D, Biankin A, Crawford HC, Morton JP, Pasca di Magliano M, Lyssiotis CA. Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell Metabolism, 2019;29:1390-1399.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, †Lyssiotis CA [†co-senior authors], †Kimmelman AC. Pancreatic Stellate Cells Support Tumor Metabolism Through Autophagic Alanine Secretion. Nature 2016;536:479–483.

Lee H-J, Kremer DM, Sajjakulnukit P, Zhang L, Lyssiotis CA. Meta-analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamics. Metabolomics, 2019.

Halbrook C, Lyssiotis CA. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell 2017;31:5–19

 

Current Student Advisees